Ticker LaunchReverse merger · Completed · LRMR
Chondrial Therapeutics, Inc.
Reverse merger with Zafgen, Inc.
Chondrial Therapeutics, Inc. merged into Zafgen, Inc., a Nasdaq-listed clinical-stage biopharmaceutical company, in a reverse merger that takes the private company public. The deal was announced on Dec 18, 2019 and closed on May 28, 2020. The combined company trades as Larimar Therapeutics, Inc. (LRMR) on Nasdaq.
Larimar Therapeutics, Inc. is a clinical-stage company developing protein replacement therapies for rare diseases, led by CTI-1601, being evaluated in a Phase 1 trial for Friedreich's ataxia.
- Status
- Completed
- Private company
- Chondrial Therapeutics, Inc.
- Public company
- Zafgen, Inc.
- Public company business before
- Nasdaq-listed clinical-stage biopharmaceutical company
- Announced
- Dec 18, 2019
- Closed
- May 28, 2020
- Combined company
- Larimar Therapeutics, Inc. (LRMR)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Concurrent financing and investors
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Jun 2, 2020
- Closing press release / exhibit
- Announcement 8-K Dec 18, 2019
- All filings on EDGAR CIK 1374690
Other completed reverse mergers
- Blockgration Global Corp.into Zoompass Holdings, Inc. · May 31, 2020
- AYRO, Inc. (AYRO Operating Company)into DropCar, Inc. · May 28, 2020
- GSL Healthcare, Inc.into Agentix Corp. · May 28, 2020
- Histogen Inc.into Conatus Pharmaceuticals Inc. · May 26, 2020
- Qualigen, Inc.into Ritter Pharmaceuticals, Inc. · May 22, 2020
- Forta Financial Group, Inc.into Financial Gravity Companies, Inc. · May 21, 2020